Information Provided By: 
Fly News Breaks for December 1, 2016
BLUE
Dec 1, 2016 | 08:05 EDT
BMO Capital analyst Matthew Luchini says that bluebird bio's Phase I data for its bb2121 product in myeloma was "impressive." The analyst notes that the overall response rate was 78%, and he adds the product to his model for the company ,estimating peak sales of about $3.6B. However, he keeps a Market Perform rating on the shares, citing the approximately 25% increase in the stock in after-hours trading.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
